1 – 10 of 29
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2024
-
Mark
A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab
(
- Contribution to journal › Article
-
Mark
EULAR recommendations for the management of ANCA-associated vasculitis : 2022 update
(
- Contribution to journal › Article
- 2023
-
Mark
First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia.
(
- Contribution to journal › Article
- 2022
-
Mark
The management of membranous nephropathy—an update
(
- Contribution to journal › Article
-
Mark
Severe infections in patients with ANCA-associated vasculitis treated with rituximab
(
- Contribution to journal › Article
-
Mark
Perspective on COVID-19 vaccination in patients with immune-mediated kidney diseases : consensus statements from the ERA-IWG and EUVAS
(
- Contribution to journal › Scientific review
- 2021
-
Mark
Rituximab in Membranous Nephropathy
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Rituximab in adult minimal change disease and focal segmental glomerulosclerosis - What is known and what is still unknown?
(
- Contribution to journal › Scientific review
-
Mark
Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab
(
- Contribution to journal › Article
-
Mark
Prime-boost vaccination strategy enhances immunogenicity compared to single pneumococcal conjugate vaccination in patients receiving conventional DMARDs, to some extent in abatacept but not in rituximab-treated patients
(
- Contribution to journal › Article